Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Deals

China Grand Pharmaceuticals Secures Distribution of Sirtex’s SIR-Spheres for Liver Cancer

Fineline Cube Dec 19, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) announced that its subsidiaries, Beijing...

Company Deals

Organon In-Licenses Eli Lilly’s Emgality and Rayvow for European Migraine Market

Fineline Cube Dec 19, 2023

Organon (NYSE: OGN), a specialist in women’s health, has in-licensed migraine treatments Emgality (galcanezumab) and...

Company Drug

European Commission Expands Keytruda Indications for Advanced Cancer Treatments

Fineline Cube Dec 19, 2023

The European Commission (EC) has granted Merck, Sharp & Dohme (MSD; NYSE: MRK) additional indications...

Company Drug

HuidaGene Secures Rare Pediatric Disease Designation for CRISPR Therapy HG302 Targeting DMD

Fineline Cube Dec 19, 2023

HuidaGene Therapeutics, based in China, has announced that it has received Rare Pediatric Disease Designation...

Company Deals

Blue Sail Medical Partners with Weifang Government on Healthcare Initiative

Fineline Cube Dec 19, 2023

China’s Blue Sail Medical Co., Ltd. (SHE: 002382) has announced strategic cooperation agreements with the...

Company Drug

HighField Biopharmaceutical Doses First Patient in HFK1 Clinical Trial Targeting Solid Tumors

Fineline Cube Dec 19, 2023

Hangzhou-based HighField Biopharmaceutical, a leader in immuno-oncology focused on innovative lipid-based therapies, has announced the...

Company Deals

Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement

Fineline Cube Dec 19, 2023

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector,...

Company Drug

EMA’s CHMP Gives Green Light to Sanofi’s Fexinidazole for Acute Sleeping Sickness Treatment

Fineline Cube Dec 19, 2023

Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Company Medical Device

BGI Genomics Receives NMPA Approval for Innovative Colorectal Cancer Detection Kit

Fineline Cube Dec 19, 2023

BGI Genomics Co., Ltd. (SHE: 300676), a leading genomics firm based in China, has announced...

Company Drug

InventisBio’s KRAS G12C Inhibitor D-1553 Advances Toward Priority Review in China

Fineline Cube Dec 19, 2023

According to the China Center for Drug Evaluation (CDE), Shanghai-based InventisBio Co., Ltd. (SHA: 688382)...

Company

GSK’s CCO Calls China a Hotbed for Innovative Molecules and Licensing Deals

Fineline Cube Dec 19, 2023

In an interview with the Financial Times, Luke Miels, Chief Commercial Officer of UK-based GlaxoSmithKline...

Company Deals

Biocytogen and Ona Therapeutics Forge Antibody Evaluation and Licensing Agreement

Fineline Cube Dec 19, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), based in China, has entered into an antibody...

Company Deals

WuXi Biologics Partners with Visen Pharmaceuticals for Lonapegsomatropin Manufacturing

Fineline Cube Dec 19, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...

Company Drug

Keytruda Gains 12th Indication Approval in China for HER2-Negative Gastric Cancer

Fineline Cube Dec 19, 2023

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its immunotherapy...

Company Drug

Sirnaomics Ltd Granted FDA Approval for Phase I RSV mRNA Vaccine Study

Fineline Cube Dec 19, 2023

Sirnaomics Ltd (HKG: 2257) has received approval from the US Food and Drug Administration (FDA)...

Company Drug

Roche Receives NMPA Approval for Ophthalmology BsAb Vabysmo (Farcimab) for Diabetic Macular Edema

Fineline Cube Dec 19, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has obtained marketing approval from...

Company Drug

Huadong Medicine Gets NMPA Green Light for Clinical Study of Ryzodeg Biosimilar

Fineline Cube Dec 19, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Deals

Fosun Pharmaceutical Secures GHIT Fund Investment for Malaria Drug Trial

Fineline Cube Dec 18, 2023

Shanghai Fosun Pharmaceutical Co., Ltd (SHA: 600196, HKG: 2196) has received financial backing of JPY...

Company Drug

FDA Approves Pfizer-Astellas-MSD Combo Therapy for Advanced Urothelial Cancer

Fineline Cube Dec 18, 2023

Pfizer (NYSE: PFE), Astellas (TYO: 4503), and Merck, Sharp & Dohme (MSD; NYSE: MRK) have...

Medical Device Policy / Regulatory

China Releases Emergency Use Rules for Medical Devices Amid Public Health Emergencies

Fineline Cube Dec 18, 2023

The National Medical Products Administration (NMPA), National Health Commission (NHC), and Chinese Center for Disease...

Posts pagination

1 … 423 424 425 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.